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IGFs are important regulators of pancreatic -cell de-
velopment, growth, and maintenance. Mutations in the
IGF genes have been found to be associated with type 2
diabetes, myocardial infarction, birth weight, and obe-
sity. These associations could result from changes in
insulin secretion. We have analyzed glucose-stimulated
insulin secretion using hyperglycemic clamps in carriers
of a CA repeat in the IGF-I promoter and an ApaI
polymorphism in the IGF-II gene. Normal and impaired
glucose-tolerant subjects (n 237) were independently
recruited from three different populations in the Neth-
erlands and Germany to allow independent replication
of associations. Both first- and second-phase insulin
secretion were not significantly different between the
various IGF-I or IGF-II genotypes. Remarkably, noncar-
riers of the IGF-I CA repeat allele had both a reduced
insulin sensitivity index (ISI) and disposition index
(DI), suggesting an altered balance between insulin
secretion and insulin action. Other diabetes-related
parameters were not significantly different for both the
IGF-I and IGF-II gene variant. We conclude that gene
variants in the IGF-I and IGF-II genes are not associ-
ated with detectable variations in glucose-stimulated in-
sulin secretion in these three independent populations.
Further studies are needed to examine the exact contri-
butions of the IGF-I CA repeat alleles to variations in ISI
and DI. Diabetes 53 (Suppl. 1):S26–S30, 2004
IGFs are regulators of processes like growth andmetabolism (1–3). IGF-I and IGF-II also contributeto pancreatic -cell growth and development byregulating -cell replication, renewal, and apoptosis
(4,5). Deregulation of the balance between -cell renewal
and apoptosis due to alterations in IGF levels is potentially
of great importance in the development of glucose intol-
erance. In addition, insulin-dependent glucose homeosta-
sis may be affected by IGFs by sharing common steps in
the signaling pathways of receptors for IGFs and insulin
(6). Defects in the IGF/insulin-signaling pathways affect
fetal growth and thus birth weight, which is a known risk
factor for type 2 diabetes and other parts of the metabolic
syndrome during life (7). Furthermore, it has been shown
in animal models that ablation of the IGF-I receptor from
pancreatic -cells results in the absence of the first phase
of glucose-stimulated insulin secretion and a strong reduc-
tion in second-phase insulin secretion (8,9). Together,
these data make it plausible that defects at the level of
IGF-I or IGF-II are associated with alterations in glucose-
stimulated insulin secretion resulting in glucose intoler-
ance.
Previously, it was shown that polymorphisms in the
IGF-I and IGF-II genes are associated with features of the
metabolic syndrome (10–13). A (CA)n repeat in the pro-
moter region of the IGF-I gene associates with type 2
diabetes, cardiovascular disease, and reduced birth weight
(10,14). Gene variants in the IGF-II gene are found in
association studies with BMI and IGF-II levels (11,12).
However, conflicting results have been reported for both
gene variants (15–17). Preliminary results, based on oral
glucose tolerance test (OGTT) data, have suggested a
-cell defect in carriers of gene variants in both genes
(13,14; N. Vaessen, personal communication).
In this study, we analyzed glucose-stimulated insulin
secretion in relation to the presence of the (CA)n repeat
polymorphism in the IGF-I gene and the ApaI polymor-
phism in the IGF-II gene (10,13). As described previously,
all participants underwent a hyperglycemic clamp at 10
mmol/l glucose to assess insulin secretion (18–20). Sub-
jects with normal glucose tolerance (NGT) (n  143) or
impaired glucose tolerance (IGT) (n  94) were recruited
from three independent studies in the Netherlands and
Germany (18–20). This allowed the independent replica-
tion of observations in different study cohorts, which
enhances the power of our approach.
RESEARCH DESIGN AND METHODS
Subjects. Participants were selected from three independent studies in the
Netherlands and Germany.
We have studied 76 subjects with NGT from Germany according the
protocols of the Tu¨bingen Family Study for Type 2 Diabetes (20). Newspaper
ads and word-of-mouth proposing diabetes screens were used to recruit
healthy volunteers for this study. Glucose tolerance status was assessed using
From the 1Deparment of Molecular Cell Biology, Leiden University Medical
Center, Leiden, the Netherlands; the 2Department of Internal Medicine,
Universita¨tsklinikum Tu¨bingen, Tu¨bingen, Germany; the 3Department of Epi-
demiology and Biostatistics, Genetic Epidemiology Unit, Erasmus University
Medical Center, Rotterdam, the Netherlands; the 4Institute for Research in
Extramural Medicine, Free University Medical Center, Amsterdam, the Neth-
erlands; and the 5Department of Internal Medicine, University Medical Center,
Utrecht, the Netherlands.
Address correspondence and reprint requests to J. Antonie Maassen, LUMC,
Department of Molecular Cell Biology, Wassenaarseweg 72, 2333 AL Leiden,
Netherlands. E-mail: j.a.maassen@lumc.nl.
Received for publication 12 March 2003 and accepted 11 June 2003.
This article is based on a presentation at a symposium. The symposium and
the publication of this article were made possible by an unrestricted educa-
tional grant from Les Laboratoires Servier.
DI, disposition index; IGT, impaired glucose tolerance; ISI, insulin sensitiv-
ity index; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test;
RFLP, restriction fragment length polymorphism.
© 2004 by the American Diabetes Association.
S26 DIABETES, VOL. 53, SUPPLEMENT 1, FEBRUARY 2004
OGTTs, and all subjects were GAD antibody negative and unrelated to each
other. The subjects participating in the study had a mean age of 36 12 years.
The Dutch NGT subjects (n  67) were partly recruited as first-degree
relatives from type 2 diabetic subjects (n  44) (18,21). The other part of this
cohort consisted of matched normoglycemic subjects. Subjects were unre-
lated to each other, and their mean age was 46  6 years. A standard OGTT
was used to define glucose tolerance status in all subjects.
Subjects with IGT (n  94) were all of Dutch origin (19). The IGT subjects
(aged 57  7 years) were detected by population screening in the city of
Hoorn. Subjects with a fasting glucose 5.5 mmol/l were invited for two
OGTTs on separate days. Those with a mean postload glucose level between
8.6 and 11.0 mmol/l were included in the study. Also in this cohort, all subjects
were unrelated to each other. The Dutch NGT and IGT groups were recruited
independently in different regions of the country. Details of the study groups
are described previously (18–20). Informed consent was obtained from all
participants, and the appropriate local medical ethics committees approved
the protocol.
Hyperglycemic clamps. Hyperglycemic clamps were performed at 10 mmol/l
in all subjects. The Dutch NGT and IGT subjects underwent a 3-h clamp. In the
German NGT subjects, the clamp lasted for 2 h. After an overnight fast, the
subjects received an intravenous glucose bolus to acutely raise glucose levels
to 10 mmol/l. Blood glucose levels were measured at the appropriate intervals
to maintain a constant blood glucose during the clamp. Blood samples for
insulin were drawn at 2.5-min intervals during the first 10 min of the clamp and
at 10- to 20-min intervals during the remainder. Exact details of the clamping
procedures in the different study groups were described previously (18–
20,22). First-phase insulin secretion was defined as the sum of the insulin
levels during the first 10 min of the clamp. Second-phase insulin secretion was
defined as the mean of the insulin values during the last 40 min (80–120 min,
NGT group, Germany) or the last 30 min (150–180 min, NGT and IGT groups,
the Netherlands) of the clamp. The insulin sensitivity index (ISI) was
determined by relating the glucose infusion rate to the plasma insulin
concentration during the last 40 min (NGT, Germany) or 30 min of the clamp.
The disposition index (DI) was calculated as the product of first-phase insulin
secretion and ISI according to Bergman et al. (23).
Genotyping. Classification of the repeat length in the IGF-I gene was as
described previously (10); carriers of the normal 192-bp allele had a repeat
length of 19 CA repeat units. All other repeat lengths were classified as
noncarrier (10). Genotypes of the ApaI polymorphism in the IGF-II gene were
determined by a PCR–restriction fragment length polymorphism (RFLP)-
based method or direct sequencing as described previously (13). The most
prevalent GG genotype was used as a reference.
Statistics. All data are presented as means SE or median with interquartile
range. ANOVA or Mann-Whitney U test was used for general comparisons
between the different genotypes. Variables were log-transformed before
analysis if necessary. Adjustments for age, sex, BMI, and study center in the
pooled analyses were done in separate general linear regression analyses for
all parameters. A priori power calculations showed that the design used in this
study would allow the detection of a difference in first or second phase of
insulin secretion between 15 and 30% with 90% power (P 0.05). Results were
regarded significant at P  0.05. Statistical analysis was performed with the
SPSS version 10.0 software (SPSS, Chicago).
RESULTS
We used three different cohorts in our studies. One of the
cohorts consisted of randomly recruited NGT subjects
from Germany. The second cohort of NGT subjects was in
part recruited as first-degree relatives of type 2 diabetic
individuals. The third cohort consisted of subjects with
IGT (18–20). The last two cohorts were independently
selected from two different regions in the Netherlands and
had both an increased risk for type 2 diabetes and evi-
dence for -cell dysfunction (22). As can be expected, the
IGT group had the lowest insulin secretion levels, ISIs, and
DIs compared with the other two NGT groups (21).
Classification of the repeat length in the IGF-I gene was as
described previously (10); carriers of the normal 192-bp
allele had a repeat length of 19 CA repeat units. All other
repeat lengths were classified as noncarrier (10). Geno-
types of the ApaI polymorphism in the IGF-II gene were
determined by a PCR-RFLP–based method as described
previously (13). Genotype frequencies for the IGF-I and
IGF-II variants were comparable between the different
cohorts and are comparable to those reported in other
Caucasian populations (Tables 1 and 2) (10–12,15). All
genotype distributions were in the Hardy-Weinberg equi-
librium (data not shown).
IGF-I promoter gene variant. We have investigated
whether the IGF-I gene variant is associated with insulin
secretion in two independent populations from the Neth-
erlands. Glucose-stimulated insulin secretion during the
hyperglycemic clamp was not significantly different be-
tween the different genotypes, both under a recessive or
dominant model (Table 1). However, we do see a reduced
ISI and DI in IGT noncarriers of the 192-bp allele (P for
trend 0.05, Table 1). Combined analysis of the Dutch
NGT and IGT groups resulted in a significant association
of the polymorphism with clamp-derived insulin sensitivity
(ISI) (P  0.01 for 192 bp/192 bp  non-192 bp/192 bp vs.
non-192 bp/non-192 bp, with adjustment for age, sex, BMI,
and study center). Furthermore, we noted a decreased DI
in noncarriers of the 192-bp allele (P 0.03 for trend, with
adjustment for age, sex, BMI, and study center). Other
diabetes-related parameters such as glucose and insulin
levels were not significantly different between the different
IGF-I genotypes (Table 1). There was no evidence for an
interaction with BMI (data not shown). Data about the
IGF-I polymorphism in the German NGT cohort are not
available.
IGF-II gene variant. Because of the low number of AA
carriers, we pooled the AA and AG genotypes of the IGF-II
gene variant in most of our analyses (Table 3). Separate
testing of the AA carriers did not essentially change our
findings. Glucose and insulin levels during OGTTs were
not significantly different between the two genotype
groups in either of the study populations (data not shown).
Also, the first phase of the glucose-stimulated insulin
secretion, as measured by hyperglycemic clamps, was not
different between the genotypes (adjusted for age, sex, and
BMI) (Table 3). We did see, however, a decreased second-
phase insulin secretion in the NGT group from the Neth-
erlands (P  0.04 for GG vs. AA  AG, adjusted for age,
sex, and BMI, Table 3). This was, however, not replicated
in the two other cohorts (Table 3). If BMI is a mediating
factor in the causal chain of the gene variant leading to
alterations in glucose metabolism, adjustment for BMI
would be an over-adjustment. However, when we repeated
the tests without BMI in the model, the results did not
change.
Insulin sensitivity, as assessed with the hyperglycemic
clamps, was not significantly different between the geno-
types in all our cohorts (Table 3). Furthermore, there was
no evidence for a gene-environment interaction with fac-
tors such as BMI and triglycerides (data not shown).
However, trends toward lower body weight and BMIs
were observed in carriers of the AA genotype without
reaching statistical significance in any of the populations
(Table 2). A pooled analysis of all three study cohorts did
not change our findings (P  0.1, data not shown).
Furthermore, we did not observe significant changes in
fasting glucose and (pro)insulin levels, lipid profiles, and
other diabetes- and/or obesity-related parameters (Table 2,
data not shown).
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DISCUSSION
It has been shown previously that IGF-I and IGF-II levels
are determinants of fetal growth and birth weight in both
humans and animals. Reduced birth weight is a known risk
factor for the development of diabetes and other features
of the metabolic syndrome (7). Genetically determined
low levels of IGFs may in part explain these observations.
Previously it was shown that both the IGF-I and IGF-II
gene variants examined in this study are associated with
reduced levels of the respective growth factors (10,11).
IGFs are also important factors for the delicate balance
between cell survival and cell death in the pancreatic
-cell (4). A disturbed balance between -cell replication
and apoptosis might result in an altered setting of the
-cell, eventually resulting in -cell failure. IGF-I and
IGF-II bind to specific receptors on the pancreatic -cell.
One of these receptors is the IGF-I receptor (8). Studies
using -cell–specific IGF-I receptor knockouts have shown
that these animals have an almost absent first and second
phase of glucose-stimulated insulin secretion (8,9). Be-
cause -cell mass is unaffected, this might be caused by
altered glucose-sensing capacities of the -cells lacking
the IGF-I receptor (8). Together, this has led us to specu-
late that genetic defects in both IGF-I and IGF-II alter
glucose-stimulated insulin secretion in humans. Prelimi-
nary data suggested a secretion defect in both carriers of
the IGF-I and IGF-II gene variants (13,14).
In this study, we have examined glucose-stimulated
insulin secretion in relation to these gene variants. From
our data, we conclude that the two gene variants in the
IGF genes are not associated with the magnitude of
glucose-stimulated insulin secretion during hyperglycemic
clamps in independent Dutch and German subjects. This
suggests that the mild variations in IGF levels associated
with the gene variants in IGF-I and IGF-II do not affect
glucose-stimulated insulin secretion. This is further cor-
roborated by the fact that IGF-I levels are not associated
with glucose-stimulated insulin secretion (24). We have
examined three cohorts with either NGT or IGT originat-
ing from three independent populations in the Netherlands
and Germany. A limited part of our populations consisted
of first-degree relatives of type 2 diabetic individuals and
subjects with IGT (18,19). Both groups have an increased
risk of developing type 2 diabetes (22). One of the early
defects in these at-risk individuals is a reduced first-phase
insulin secretion (22). If mutations in the IGF genes are
associated with altered glucose-stimulated insulin secre-
tion, we expect this should be first manifest in these at-risk
individuals. With respect to changes in (first-phase) insulin
secretion, we did not observe any association. We cannot,
however, exclude the possibility that changes in insulin
secretion only become manifest after stressing glucose
homeostasis, for instance during overfeeding. Previously,
it has been shown that carriers of the IGF-II gene variant
have an altered insulin response during an OGTT after a
100-day period of overfeeding (13).
We observed a reduced ISI and DI associated with the
CA repeat polymorphism in the IGF-I gene, suggesting an
altered balance between insulin sensitivity and insulin
secretion. Previously, it has been shown that the ISI as
measured with the hyperglycemic clamp technique corre-
lates very well with the values obtained by the “goldTA
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standard” hyperinsulinemic-euglycemic clamp (25). It has
also been shown that a hyperbolic relationship exists
between insulin secretion and insulin sensitivity. This
hyperbolic relationship can be mathematically described
by the multiplication of indexes for (first-phase) insulin
secretion and insulin sensitivity, which is referred to as the
disposition index (23). Subjects with type 2 diabetes have
a lower DI than normoglycemic subjects. A low DI indi-
cates an inability of the -cell to adapt adequately to
changes in insulin sensitivity. It is conceivable that, under
circumstances of deterioration of insulin action, as occurs
in obesity, this situation will lead to (further) deterioration
of glucose homeostasis and may consequently lead to type
2 diabetes. Whether this is the case in noncarriers of the
normal CA repeat allele of the IGF-I promoter gene is so
far not known.
The exact mechanism by which IGF-I affects insulin
sensitivity is unclear but might involve shared components
of the IGF-I/insulin-signaling pathway (6). This phenome-
non has been observed in mice lacking IGF-I expression in
the liver. These mice show muscle insulin resistance most
likely due to defects at the level of the insulin receptor
(26). Furthermore, it is known that IGF-I levels affect
insulin sensitivity in humans as well (3). Further studies
are necessary to examine the relationship between the CA
repeat in the IGF-I promoter and insulin resistance and
reduced DI in detail.
We conclude that gene variants in the IGF-I and IGF-II
genes are not associated with detectable alterations in
glucose-stimulated insulin secretion in three independent
study populations from the Netherlands and Germany.
However, our findings of a reduced ISI and a reduced DI in
noncarriers of the normal CA repeat allele in the IGF-I
promoter may point to a disturbed adaptation of -cells to
insulin action and warrants further study, especially in
obese (insulin-resistant) subjects.
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